Condition: Hypertriglyceridemia, Familial · Sponsor: GeneCradle Inc
The study will evaluate safety and tolerance of intravenous delivery of GC304 gene therapy drug as a treatment of primary hypertriglyceridemic patients with previous onset of acute pancreatitis.
This description comes directly from the study's public registry record.
GeneCradle, Inc. China · 86-13501380583 · ind@bj-genecradle.com
Always discuss trial participation with your own doctor first.
| Peking Union Medical College | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05860569